TGF-β inhibitors for the treatment of cancer

被引：65
|
作者：
Lahn, M [1 ]
Kloeker, S [1 ]
Berry, BS [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Therapeut Area Oncol, Indianapolis, IN 46285 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 06期
关键词：
antisense oligonucleotide; cancer; clinical Studies; knockout mice; monoclonal antibodies; TGF-beta; TGF-beta RI kinase inhibitors;
D O I：
10.1517/13543784.14.6.629
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Advances in understanding the role of transforming growth factor (TGF)-beta in tumorigenesis have led to the development of TGF-beta inhibitors for cancer treatment. Three platforms of TGF-beta inhibitors have evolved: antisense oligonucleotides, monoclonal antibodies and small molecules. in this review, the current stage of development of each known TGF-beta inhibitor will be discussed. As part of the risk/benefit assessment of TGF-beta inhibitors, the known effects of TGF-beta deficiency in mice, non-clinical toxicology studies with TGF-beta inhibitors in rats, and the clinical studies with monoclonal antibodies against TGF-beta will be summarised.
引用
收藏
页码：629 / 641
页数：13
相关论文
共 50 条
  • [31] TGF-β in cancer and as a therapeutic target
    Pinkas, Jan
    Teicher, Beverly A.
    BIOCHEMICAL PHARMACOLOGY, 2006, 72 (05) : 523 - 529
  • [32] Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
    Ungefroren, Hendrik
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (08) : 679 - 693
  • [33] A control engineering approach to understanding the TGF-β paradox in cancer
    Chung, Seung-Wook
    Cooper, Carlton R.
    Farach-Carson, Mary C.
    Ogunnaike, Babatunde A.
    JOURNAL OF THE ROYAL SOCIETY INTERFACE, 2012, 9 (71) : 1389 - 1397
  • [34] Roles for the type III TGF-β receptor in human cancer
    Gatza, Catherine E.
    Oh, Sun Young
    Blobe, Gerard C.
    CELLULAR SIGNALLING, 2010, 22 (08) : 1163 - 1174
  • [35] The Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis
    Mallikarjuna, Pramod
    Zhou, Yang
    Landstrom, Marene
    BIOMOLECULES, 2022, 12 (05)
  • [36] Disruption of the TGF-β pathway and modeling human cancer in mice
    Letterio, JJ
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 576 (1-2) : 120 - 131
  • [37] TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
    Dahmani, Amina
    Delisle, Jean-Sebastien
    CANCERS, 2018, 10 (06)
  • [38] CircRNAs: Pivotal modulators of TGF-β signalling in cancer pathogenesis
    Bhat, Asif Ahmad
    Gupta, Gaurav
    Dahiya, Rajiv
    Thapa, Riya
    Gahtori, Archana
    Shahwan, Moyad
    Jakhmola, Vikas
    Tiwari, Abhishek
    Kumar, Mahish
    Dureja, Harish
    Singh, Sachin Kumar
    Dua, Kamal
    Kumarasamy, Vinoth
    Subramaniyan, Vetriselvan
    NON-CODING RNA RESEARCH, 2024, 9 (02): : 277 - 287
  • [39] Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling
    Parichatikanond, Warisara
    Luangmonkong, Theerut
    Mangmool, Supachoke
    Kurose, Hitoshi
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7
  • [40] Reversal of Tumor-induced Immunosuppression by TGF-β Inhibitors
    Slawomir Wojtowicz-Praga
    Investigational New Drugs, 2003, 21 : 21 - 32
12345